[bis(pom)J derivatives of various acyclic nucleoside phosphonates-9-(2-phosphonylmethoxyethyl)adenine (PMEA), 9-(2-phosphonylmethoxypropyl)adenine (PMPA), and 9-(2-phosphonylmethoxypropyl)diaminopurine (PMPDAP)-were found to exhibit 9-to 23-fold greater antiviral activity than their corresponding unmodified compounds. The cytotoxicity of the bis(pom) analogs was also increased by various degrees, thus altering the therapeutic indexes of these compounds. Metabolic studies using [3H]bis-(pom)PMEA and [3H]PMEA as model compounds suggested a > 100-fold increase in the cellular uptake of the bis(pom) derivative and formation of active diphosphorylated metabolite. However, the bis(pom) derivatives were chemically unstable and highly susceptible to serum-mediated hydrolysis, factors which limit their potential utility for intracellular drug delivery.
Acyclic nucleoside phosphonate analogs of both purine and pyrimidine bases show a broad-spectrum antiviral activity against several RNA and DNA viruses (reviewed in reference 4). The adenine analog, 9-(2-phosphonylmethoxyethyl)adenine (PMEA), is active against human immunodeficiency virus type 1 (HIV-1) and other retroviruses, including HIV-2, simian immunodeficiency virus, feline immunodeficiency virus, and Moloney murine sarcoma virus. PMEA is also active against various herpesviruses, including herpes simplex virus type 1 (HSV-1), HSV-2, cytomegalovirus, and Epstein-Barr virus. Thus, PMEA is of interest both as a potential antiretroviral drug for HIV-1 infections and also for the treatment of some of the opportunistic infections associated with AIDS, and it is currently undergoing a phase I and II trial for the evaluation of its toxicity and/or efficacy in AIDS patients. The related phosphonate analogs 9-(2-phosphonylmethoxypropyl)adenine (PMPA) and 9-(2-phosphonylmethoxypropyl)diaminopurine (PMPDAP) exhibit potent anti-HIV activity, although these compounds are less effective against herpesviruses. The phosphonyl groups exhibit a negative charge at the physiological pH, and hence the cellular uptake and bioavailability (in rats) of these molecules with oral drug administration are relatively poor (8) . Recently, bis(pivaloyloxymethyl) [bis-(pom)] esters of the antitumor nucleotide analogs 5-fluoro-2'-deoxyuridine were shown to function as membrane-permeable prodrugs and inhibit proliferation of both wild-type and thymidine kinase-deficient murine leukemia cells (5, 9) . Similarly, a bis(pom) ester of PMEA was found to have increased anti-herpes simplex virus activity in vitro compared with PMEA (11) . However, the mechanisms involved in the increased activity of the bis(pom) derivative were not determined. In addition, little is known about the stability of the bis(pom) derivatives or their bioconversion to the active * Corresponding author. intracellular metabolites. In this study, we have evaluated the anti-HIV activity of bis(pom) esters of PMEA, PMPA, and PMPDAP and their metabolism in human lymphoid cell lines. Table 1 summarizes the anti-HIV and cytotoxic activities of the various phosphonates and their bis(pom) derivatives. The antiviral activities of the different compounds against HIV-1IIIB replication in MT-2 cells were monitored by XTT assays performed as previously described (12) . The cytotoxicities of these compounds against MT-2 cells were evaluated by a dye conversion-cell viability assay (12) . Compared with the unmodified analogs, the bis(pom) derivatives were biologically more active and showed enhanced antiviral activities. The cytotoxicities of these compounds were also enhanced to various degrees ( Table 1 ). The activities of these compounds are likely to be greater than the values shown in Table 1 , since the XTT assay is relatively insensitive compared with other methods. The antiviral versus cytotoxic activities were enhanced to various degrees after bis(pom) modification, thus altering the therapeutic index (ratio of cytotoxicity to antiviral efficacy) of the unmodified and bis(pom)-modified compounds. Bis(pom)PMEA and bis-(pom)PMPDAP showed approximately fourfold lower therapeutic indexes than their unmodified analogs, while the therapeutic index of bis(pom)PMPA was comparable with that of PMPA. The differences in the extent of accumulation of the intracellular metabolites from these analogs and their inhibitory potencies against the target enzymes may account for the observed effects.
To gain some understanding of the biochemical basis for the potency of the bis(pom) derivatives, we compared the metabolisms of bis(pom)PMEA and PMEA in MT-2 cells. The metabolisms of PMEA and bis(pom)PMEA were studied by previously described procedures (1) (2) (3) 6 1A) . By contrast, only a small proportion (<1%) of the label, which was distributed primarily in PMEA, PMEAp, and PMEApp, appeared within PMEA-treated cells (Fig. 1B) . However, a small proportion of the label was found to be incorporated into additional metabolites, primarily ATP; we attribute this to some radioactive adenine present as a contaminant. The time courses of intracellular metabolism of bis(pom)P-MEA and PMEA in MT-2 cells are shown in Fig. 2 . Cells incubated with 1 ,M bis(pom)PMEA showed a rapid accumulation of PMEA which after 2 h reached a peak concentration of 200 pmol/106 cells ( Fig. 2A) . The intracellular PMEA level decreased thereafter, but relatively high levels (-25 pmolI106 cells) were seen even after 8 h of incubation.
By contrast, much lower levels of PMEA were detected in the MT-2 cells incubated with a 10-fold higher concentration of PMEA (Fig. 2B) . The intracellular concentrations of PMEAp and PMEApp formed from bis(pom)PMEA increased during the initial 6 h of incubation and plateaued at concentrations of 25 and 80 pmol/106 cells, respectively. This contrasts sharply with the low levels of PMEAp and PMEApp accumulated in cells incubated with PMEA. At any time point tested, the intracellular level of bis(pom)P-MEA or mono(pom)PMEA, a presumed intermediate (5), was < 1.0% of the level of PMEA or its metabolites ( Fig. 2A,  inset) .
We also determined the extracellular concentrations of the drug or drug metabolites in [3H]bis(pom)PMEA-treated MT-2 cell cultures (Fig. 3A) . Bis(pom)PMEA was rapidly cleared from the medium (half-life, -100 min). A large amount of mono(pom)PMEA accumulated in the culture medium within 30 min, and the levels declined gradually thereafter. This accumulation of mono(pom)PMEA in medium contrasts with the very low level of the mono(pom)P-MEA detected in the cells ( Fig. 2A, inset) and indicates that the formation of mono(pom)PMEA probably occurs predominantly extracellularly. PMEA was also detected in the culture medium, and PMEA levels progressively increased with time. However, at any given time point, the extracellular PMEA level constituted only a small fraction of the intracellular concentration. Finally, the stability of [3H]bis-(pom)PMEA in cell-free medium was examined in the pres- cephalosporin for the treatment of bacterial infections without any deleterious effects (7, 10 
